The plant is scheduled to open sometime in 2031, as part of the company's larger push to expand its production capacity for obesity drugs that have exploded in popularity.

Three major policy and market forces are shaping the pharmaceutical landscape in 2026.

Many brands focus on visible consumer-facing initiatives. But it's really at the supply chain level where a brand is going to have the greatest impact

Most biopharma manufacturing and shipping is outsourced to CMOs and 3PLs, leaving a biotech firm with limited visibility into its shipment lifecycle.

The requirement to manually perform regular checks and balances on enterprise procurement has often been viewed as slowing the speed of business and limiting corporate agility. 

GLP-1 drugs are forcing companies to adapt to a sustained shift in consumer behavior and healthcare demand that touches both food and pharma supply chains.

Attendees of Manifest 2026 will get the opportunity to attend presentations by the three winners.

For supply chain, logistics, and finance leaders, understanding the true impact of the 2026 GRI is no longer optional. This guide equips teams with the insight needed to anticipate change, protect margins, and make smarter parcel strategy decisions in an environment where pricing never stands still. 

Greggs said people's dietary changes, and a “broader health trend” have led it to move away from its best-selling but high-fat pasties, cakes and pastries

President Donald Trump’s strategy of reducing the U.S.-China trade deficit is bringing down the volume of both imports and exports.